Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Kura Oncology (KURA) PT Lowered to $32 at H.C. Wainwright
November 24, 2021 10:20 AM ESTH.C. Wainwright analyst Joseph Pantginis lowered the price target on Kura Oncology (NASDAQ: KURA) to $32.00 (from $43.00) while maintaining a Buy rating.
The analyst commented, "This morning, Kura announced the FDA has placed a partial clinical hold on the KOMET-001 Phase 1b study evaluating KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML). The hold was put in place... More
